Incyte Investor Relations Material
Latest events
Investor Update
Incyte
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Incyte Corporation
Access all reports
Incyte is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company develops next generation medicines across its three core therapeutic platforms: cancer immunology, epigenetics and targeting microRNAs. The company's epigenetics platform is focused on technologies that can reprogram adult cells to their embryonic state to make them fertile ground for drug discovery.
Key slides for Incyte Corporation
Q1 2025
Incyte Corporation
Q1 2025
Incyte Corporation
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
INCY
Country
🇺🇸 United States